Skip to main content
Advertisement
Advertisement

KRRO

KRRO logo

Korro Bio, Inc. Common Stock

9.83
USD
Sponsored
-0.51
-4.93%
Sep 23, 15:59 UTC -4
Closed
exchange

After-Market

9.82

-0.01
-0.10%

KRRO Earnings Reports

Positive Surprise Ratio

KRRO beat 16 of 28 last estimates.

57%

Next Report

Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$170.00K
/
-$1.28
Implied change from Q2 26 (Revenue/ EPS)
--
/
+19.63%
Implied change from Q3 25 (Revenue/ EPS)
-84.40%
/
-33.33%

Korro Bio, Inc. Common Stock earnings per share and revenue

On Aug 06, 2026, KRRO reported earnings of -1.07 USD per share (EPS) for Q2 26, beating the estimate of -1.47 USD, resulting in a 27.65% surprise. Revenue reached --, compared to an expected 218.57 thousand, with a -100.00% difference. The market reacted with a +5.39% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -1.28 USD, with revenue projected to reach 170.00 thousand USD, implying an increase of 19.63% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Korro Bio, Inc. Common Stock reported EPS of -$1.07, beating estimates by 27.65%, and revenue of $0.00, -100% below expectations.
The stock price moved up 5.39%, changed from $11.50 before the earnings release to $12.12 the day after.
The next earning report is scheduled for Nov 10, 2026.
Based on 9 analysts, Korro Bio, Inc. Common Stock is expected to report EPS of -$1.28 and revenue of $170.00K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement